Were there any specific populations for sapropterin's safety assessment?

Were any specific populations included in sapropterin’s safety assessment?

Yes. Sapropterin’s safety assessment included specific patient populations, including pediatric groups and patients with varying levels of renal and hepatic function, as part of the clinical program and subgroup analyses reported for the drug. These groups were evaluated for safety outcomes such as adverse events and discontinuations due to adverse events. [1][2]

How were pediatric patients evaluated for safety?

Pediatric patients were a defined part of the sapropterin safety evaluation, with safety data collected across childhood age ranges relevant to the indication. The assessment focused on how frequently adverse events occurred and whether safety signals differed in younger patients compared with older age groups. [1]

What about people with kidney or liver impairment?

Patients with impaired renal and/or hepatic function were included as specific subpopulations in the safety assessment. The goal was to check whether impairment changed the safety profile or tolerability of sapropterin compared with patients without those impairments. [2]

Were there any other subgroups emphasized?

The safety assessment also considered other subgroup factors reflected in the clinical safety datasets, such as baseline disease characteristics tied to the drug’s intended use. The reporting emphasized whether adverse event patterns differed across those groups. [1][2]

Sources

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/